Patents by Inventor Jes Thorn Clausen

Jes Thorn Clausen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
    Patent number: 10457743
    Abstract: The present invention relates to an antibody that specifically binds to an epitope in the N-terminal part (residues 1 to 79) of tissue factor pathway inhibitor (TFPI). An antibody according to the invention may be capable of neutralising TFPI inhibition of the TF/FVIIa complex, even in the presence of elevated levels of TFPI. Such antibodies may find utility in the treatment of subjects with a coagulopathy, such as those with haemophilia A or B, with or without inhibitors.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: October 29, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Jes Thorn Clausen, Berit Olsen Krogh, Helle Heibroch Petersen, Cecilia Augustsson
  • Antibodies Against Tissue Factor Pathway Inhibitor
    Publication number: 20190211112
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 11, 2019
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Targeting tissue factor to activated platelets
    Publication number: 20190062429
    Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
    Type: Application
    Filed: September 13, 2018
    Publication date: February 28, 2019
    Inventors: Ida Hilden, Lars Christian Petersen, Jens Breinholt, Mette Dahl Andersen, Jais Rose Bjelke, Thomas Egebjerg, Jes Thorn Clausen, Susanne Nedergaard Grell
  • Targeting tissue factor to activated platelets
    Patent number: 10106606
    Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: October 23, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Lars Christian Petersen, Jens Breinholt, Mette Dahl Andersen, Jais Rose Bjelke, Thomas Egebjerg, Jes Thorn Clausen, Susanne Nedergaard Grell
  • Antibodies Against Tissue Factor Pathway Inhibitor
    Publication number: 20170114147
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Application
    Filed: January 6, 2017
    Publication date: April 27, 2017
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Antibodies against tissue factor pathway inhibitor
    Patent number: 9574011
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 21, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Antibodies Recognizing the N-Terminal Part of Tissue Factor Pathway Inhibitor Capable of Eliciting Pro-Coagulant Activity
    Publication number: 20160152729
    Abstract: The present invention relates to an antibody that specifically binds to an epitope in the N-terminal part (residues 1 to 79) of tissue factor pathway inhibitor (TFPI). An antibody according to the invention may be capable of neutralising TFPI inhibition of the TF/FVIIa complex, even in the presence of elevated levels of TFPI. Such antibodies may find utility in the treatment of subjects with a coagulopathy, such as those with haemophilia A or B, with or without inhibitors.
    Type: Application
    Filed: July 18, 2014
    Publication date: June 2, 2016
    Inventors: Jes Thorn Clausen, Berit Olsen Krogh, Helle Heibroch Petersen, Cecilia Augustsson
  • Antibodies that are capable of specifically binding tissue factor pathway inhibitor
    Patent number: 9260518
    Abstract: The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: February 16, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Jes Thorn Clausen, Lars Christian Petersen, Brit Binow Soerensen, Helle Heibroch Petersen
  • Antibodies that are capable of specifically binding tissue factor pathway inhibitor
    Patent number: 9228022
    Abstract: The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralizing free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: January 5, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Jes Thorn Clausen, Lars Christian Petersen, Brit Binow Soerensen, Helle Heibroch Petersen, Anders Svensson
  • Therapeutic factor VIII antibodies
    Patent number: 9062115
    Abstract: The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: June 23, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Oestergaard, Ida Hilden, Heidi Lindgreen Holmberg, Kasper Lamberth, Jes Thorn Clausen
  • Anti-Human Interleukin-20 Antibodies
    Publication number: 20140194599
    Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.
    Type: Application
    Filed: August 21, 2013
    Publication date: July 10, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Jesper Pass, Soeren Oestergaard, Jes Thorn Clausen
  • Anit-Human Interleukin-20 Antibodies
    Publication number: 20140141001
    Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.
    Type: Application
    Filed: August 21, 2013
    Publication date: May 22, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Jesper Pass, Soeren Oestergaard, Jes Thorn Clausen
  • Methods of treating coagulopathies using antibodies against tissue factor pathway inhibitor
    Patent number: 8652471
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 18, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Antibodies against tissue factor pathway inhibitor (TFPI)
    Patent number: 8618263
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: December 31, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Jes Thorn Clausen
  • Antibodies Against Tissue Factor Pathway Inhibitor (TFPI)
    Publication number: 20130344090
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Ida Hilden, Jes Thorn Clausen
  • THERAPEUTIC FACTOR VIII ANTIBODIES
    Publication number: 20130266576
    Abstract: The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.
    Type: Application
    Filed: September 15, 2011
    Publication date: October 10, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Henrik Oestergaard, Ida Hilden, Heidi Lindgreen Holmberg, Kasper Lamberth, Jes Thorn Clausen
  • Antibodies Against Tissue Factor Pathway Inhibitor
    Publication number: 20130251722
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Application
    Filed: December 20, 2012
    Publication date: September 26, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Antibodies Against Tissue Factor Pathway Inhibitor
    Publication number: 20130251721
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Application
    Filed: December 20, 2012
    Publication date: September 26, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor
    Publication number: 20130253173
    Abstract: The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
    Type: Application
    Filed: February 28, 2013
    Publication date: September 26, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Ida Hilden, Jes Thorn Clausen, Lars Christian Petersen, Brit Binow Soerensen, Helle Heibroch Petersen, Anders Svensson
  • Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor
    Publication number: 20130142804
    Abstract: The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
    Type: Application
    Filed: June 30, 2011
    Publication date: June 6, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Ida Hilden, Jes Thorn Clausen, Lars Christian Petersen, Brit Binow Soerensen, Helle Heibroch Petersen